HCSG
Healthcare Services Group, Inc.
HCSG offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over HCSG overall, supported by stronger fundamentals.
HCSG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
HCSG's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HCSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.02 | — |
| Cheap | 19x | $28.51 | +14% |
| Forward | 21x | $25.02 | — |
| Fair | 24x | $35.09 | +40% |
| Expensive | 35x | $52.32 | +109% |
Historical ranges are pointers, not guarantees.
HCSG has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HCSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for HCSG, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over HCSG on the outlook, with more favorable valuation expectations.
HCSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.18 | -20% |
| Q3 2026 | $1.48 | +179% |
| Q2 2026 | $1.71 | +1215% |
| Q1 2026 | $0.95 | +73% |
| Q4 2025 | $0.81 | +53% |
| Q3 2025 | $0.53 | -22% |
| Q2 2025 | $0.13 | -69% |
| Q1 2025 | $0.55 | -1.8% |
| Q4 2024 | $0.53 | +1.9% |
HCSG earned $1.48 per share over the past year, up 179% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HCSG on earnings, with more consistent year-over-year improvement.
HCSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $479.6M | +3.3% |
| Q2 2026 | $470.8M | +2.7% |
| Q1 2026 | $462.8M | +3.4% |
| Q4 2025 | $466.7M | +6.6% |
| Q3 2025 | $464.3M | +8.5% |
| Q2 2025 | $458.5M | +7.6% |
| Q1 2025 | $447.7M | +5.7% |
| Q4 2024 | $437.8M | +3.3% |
HCSG's revenue has grown year over year for 11 quarters in a row: $480M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | -5.3 points |
| Q2 2026 | 6.6% | +16 points |
| Q1 2026 | 7.5% | +2.1 points |
| Q4 2025 | 6.1% | +2.7 points |
| Q3 2025 | 12% | +8 points |
| Q2 2025 | -9.1% | -8.7 points |
| Q1 2025 | 5.3% | +0.3 points |
| Q4 2024 | 3.4% | -3.9 points |
HCSG's operating margin was 7% last quarter, down 5.3 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HCSG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HCSG on profitability, with a higher operating margin.
HCSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.1M | -60% |
| Q2 2026 | $20.2M | -26% |
| Q1 2026 | $42.3M | +64% |
| Q4 2025 | $16M | -54% |
| Q3 2025 | $70M | +2302% |
| Q2 2025 | $27.4M | +83% |
| Q1 2025 | $25.8M | +$54M |
| Q4 2024 | $34.8M | -28% |
HCSG still generates free cash flow, though less than at its 2020 peak: $107M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HCSG on cash flow, with more consistent year-over-year improvement.
HCSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -526K shares |
| 1 year | -4.9% | -3.6M shares |
| 3 years | -6.7% | -5M shares |
| 5 years | -7.6% | -5.7M shares |
| Available history | -7% | -5.2M shares |
HCSG has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11.7M |
| Q2 2026 | $20.9M |
| Q1 2026 | $24M |
| Q4 2025 | $19.6M |
| Q3 2025 | $27.3M |
| Q2 2025 | $7.7M |
| Q1 2025 | $7M |
| Q4 2024 | $1M |
HCSG spent $76M buying back its own shares over the past year, up 77% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HCSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -1.4x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -2.6x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
HCSG has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HCSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 70.5 | Neutral |
HCSG's weekly RSI is 61 (neutral) and its Stochastic is 71 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HCSG PE vs Healthcare Sector
| Metric | HCSG | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 35% below |
| PE % | 6 | 29 | 23 pts below |
HCSG has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HCSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.9 | 9.5% above |
| 20 week MA | $22.9 | 9.4% above |
| 50 week MA | $21.3 | 17% above |
| 100 week MA | $17.5 | 43% above |
| 200 week MA | $14.7 | 71% above |
HCSG is in an uptrend: it's above all five of its weekly moving averages, and 71% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
HCSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.3 | $27.1 | +11% |
| 2021 | $27.1 | $17.2 | -37% |
| 2022 | $17.2 | $12.2 | -29% |
| 2023 | $12.2 | $10.4 | -15% |
| 2024 | $10.4 | $11.5 | +11% |
| 2025 | $11.5 | $19.6 | +70% |
| 2026 YTD | $19.6 | $25.0 | +27% |
HCSG has finished lower in three of the last six years. It's up 27% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HCSG on returns for 2026, with the stronger performance.